13F HOLDINGS REPORT
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q1 2024 · Filed May 13, 2024 · Accession 0001910264-24-000003
Total Value
$364.1M
Positions
6
Other Managers
0
Confidential Omitted
No
Holdings (6)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | ARCELLX INC | ACLX | 2,346,630 | $163.2M | 44.83% |
| 2 | CRISPR THERAPEUTICS AG | CRSP | 1,048,951 | $71.5M | 19.64% |
| 3 | ARS PHARMACEUTICALS INC | SPRY | 4,012,903 | $41.0M | 11.26% |
| 4 | NKARTA INC | NKTX | 3,333,333 | $36.0M | 9.90% |
| 5 | DESIGN THERAPEUTICS INC | DSGN | 6,526,476 | $26.3M | 7.22% |
| 6 | MINERALYS THERAPEUTICS INC | MLYS | 2,016,822 | $26.0M | 7.15% |